AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17298349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane (FP-HFA) inhaled through the nose using a large volume spacer attached to a face mask
Number of subjects: 60
Study 17298349 — intervention group
Group type: COMPARATOR
Intervention: Nasal spray of isotonic saline plus oral inhalation of FP-HFA through a mouthpiece attached to the same spacer
Number of subjects: 60
Study 15532807 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP)
Number of subjects: 126
Study 15532807 — intervention group
Group type: COMPARATOR
Intervention: No Omentoplasty (NO)
Number of subjects: 126
Study 15229463 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) alone in standard de Gramont regimen (400 mg/m(2) bolus plus 600 mg/m(2) infusion)
Number of subjects: 31
Study 15229463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) plus oxaliplatin (85 mg/m(2)) in standard de Gramont regimen
Number of subjects: 31
Study 15229463 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) alone in modified de Gramont regimen (400 mg/m(2) bolus plus 2400 mg/m(2) infusion)
Number of subjects: 31
Study 15229463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) plus oxaliplatin (85 mg/m(2)) in modified de Gramont regimen
Number of subjects: 31
Study 15229463 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of oxaliplatin as a covariate in NONMEM analysis
Number of subjects: 31
Study 11069821 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized single-breath method (ST)
Number of subjects: 115
Study 11069821 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified single-breath, flow-driven method (FD)
Number of subjects: 115
Study 11069821 — intervention group
Group type: EXPERIMENTAL
Intervention: ENO levels measured with ST method
Number of subjects: 115
Study 11069821 — intervention group
Group type: EXPERIMENTAL
Intervention: ENO levels measured with FD technique
Number of subjects: 115
Study 11069821 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ENO levels between ST and FD methods
Number of subjects: 115
Study 11069821 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ENO values in steroid-naive vs steroid-treated asthmatic children
Number of subjects: 115
Study 9244913 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual score
Number of subjects: 25
Study 9244913 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory spiral density mask -850 HU
Number of subjects: 25
Study 9244913 — intervention group
Group type: COMPARATOR
Intervention: Visual score and expiratory density mask -850 HU
Number of subjects: 25
Study 9244913 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual lung volume measured with expiratory spiral CT
Number of subjects: 25
Study 8474806 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 44
Study 8474806 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study 8474806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 3751735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (40 mg)
Number of subjects: 0
Study 3751735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (80 mg)
Number of subjects: 0
Study 3751735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripelennamine (50 mg)
Number of subjects: 0
Study 3751735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripelennamine (100 mg)
Number of subjects: 0
Study 3751735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine and tripelennamine combination
Number of subjects: 0
Study 3751735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28656811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1
Number of subjects: 617
Study 28656811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2
Number of subjects: 617
Study 28656811 — intervention group
Group type: COMPARATOR
Intervention: Nonsense Control
Number of subjects: 617
Study 28656811 — intervention group
Group type: COMPARATOR
Intervention: Distraction Control
Number of subjects: 617
Study 28656811 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Experimental Groups
Number of subjects: 617
Study 27208596 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture‐picture evaluative conditioning (EC) procedure, pairing soda images with disgust images and water images with pleasant images.
Number of subjects: 84
Study 27208596 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no pairing of images).
Number of subjects: 84
Study 27208596 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture‐picture evaluative conditioning (EC) procedure.
Number of subjects: 84
Study 23723326 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitive cardiac troponin T (hs-cTnT)
Number of subjects: 4197
Study 23723326 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) >400 ng/l
Number of subjects: 4197
Study 22950600 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (100 mg/day for 2 months)
Number of subjects: 60
Study 22950600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 19465537 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose MPH (0.6 mg/kg)
Number of subjects: 106
Study 19465537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MPH (0.3 mg/kg)
Number of subjects: 106
Study 19465537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 18421273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification
Number of subjects: 2921
Study 18421273 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 2921
Study 18421273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2921
Study 16139336 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH+E
Number of subjects: 60
Study 16139336 — intervention group
Group type: COMPARATOR
Intervention: bivalirudin
Number of subjects: 60
Study 12637462 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR plus CPM
Number of subjects: 1131
Study 12637462 — intervention group
Group type: COMPARATOR
Intervention: 5'‐DFUR alone
Number of subjects: 1131
Study 10471602 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled olprinone
Number of subjects: 9
Study 10471602 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 9
Study 10471602 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 9
Study 8918172 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer led intervention group
Number of subjects: 0
Study 8918172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult led intervention group
Number of subjects: 0
Study 8918172 — intervention group
Group type: COMPARATOR
Intervention: Nonequivalent comparison group
Number of subjects: 0
Study 1984763 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 36
Study 1984763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6416401 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical injection after diagnosis by selective tissue tension technique
Number of subjects: 77
Study 6416401 — intervention group
Group type: COMPARATOR
Intervention: Tender or trigger point localisation injection
Number of subjects: 77
Study 30715132 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive subsymptom threshold aerobic exercise
Number of subjects: 103
Study 30715132 — intervention group
Group type: COMPARATOR
Intervention: Progressive placebo‐like stretching program
Number of subjects: 103
Study 28498655 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzimidazole DGAT1 inhibitor 9
Number of subjects: 0
Study 28498655 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25828621 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/day TT and 103 mg/day PMF
Number of subjects: 240
Study 25828621 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 mg/day TT and 32 mg/day PMF
Number of subjects: 240
Study 25828621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 25828621 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/day TT and 103 mg/day PMF, 27 mg/day TT and 32 mg/day PMF, and Placebo
Number of subjects: 240
Study 23950599 — intervention group
Group type: EXPERIMENTAL
Intervention: ALAnerv® (2 pills/day for two weeks)
Number of subjects: 28
Study 20624784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 270
Study 20624784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus everolimus
Number of subjects: 270
Study 20624784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus lapatinib
Number of subjects: 270
Study 20624784 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone or plus trastuzumab
Number of subjects: 270
Study 19319017 — intervention group
Group type: EXPERIMENTAL
Intervention: Green banana (GB) diet (250 g/L) with rice-based diet (54 kcal/dL) for 5 days
Number of subjects: 73
Study 19319017 — intervention group
Group type: COMPARATOR
Intervention: Control group (rice-based diet without GB) for 5 days
Number of subjects: 73
Study 18038549 — intervention group
Group type: EXPERIMENTAL
Intervention: Superlymph (immunotropic drug with direct antimicrobial action)
Number of subjects: 0
Study 18038549 — intervention group
Group type: EXPERIMENTAL
Intervention: Superlymph (monotherapy for CABP)
Number of subjects: 0
Study 18038549 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison with healthy subjects)
Number of subjects: 0
Study 18038549 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (during treatment)
Number of subjects: 0
Study 15507066 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP vaccine (Group 1, n=39)
Number of subjects: 125
Study 15507066 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMP conjugate vaccine (Group 2, n=44)
Number of subjects: 125
Study 15507066 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D conjugate vaccine (Group 3, n=42)
Number of subjects: 125
Study 11982666 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted stair climbing exercise (SCE)
Number of subjects: 45
Study 11982666 — intervention group
Group type: COMPARATOR
Intervention: Standardized walking program (WALK)
Number of subjects: 45
Study 9718095 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 8
Study 9718095 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with low-frequency electrical stimulation (2 Hz)
Number of subjects: 8
Study 9718095 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 8
Study 9718095 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation
Number of subjects: 8
Study 7715645 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (consultation)
Number of subjects: 2353
Study 7715645 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2353
Study 2744176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh semen
Number of subjects: 155
Study 2744176 — intervention group
Group type: COMPARATOR
Intervention: Glycerol-preserved semen
Number of subjects: 155
Study 2744176 — intervention group
Group type: COMPARATOR
Intervention: TEST-yolk-preserved semen
Number of subjects: 155
Study 414083 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 22
Study 414083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7199997 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion at a constant rate of 1 mmol/min
Number of subjects: 8
Study 7199997 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 8
Study 7199997 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 8
Study 30234848 — intervention group
Group type: EXPERIMENTAL
Intervention: OVRT test battery
Number of subjects: 50
Study 30234848 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study 29388344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive format of education (2-day period)
Number of subjects: 0
Study 29388344 — intervention group
Group type: COMPARATOR
Intervention: Non-intensive format of education (series of shorter regular workshops)
Number of subjects: 0
Study 26851872 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (1 mg/mL)
Number of subjects: 100
Study 26851872 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (5000 IU/mL)
Number of subjects: 100
Study 24890307 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot running
Number of subjects: 36
Study 24890307 — intervention group
Group type: COMPARATOR
Intervention: Cushioned running shoes
Number of subjects: 36
Study 24890307 — intervention group
Group type: COMPARATOR
Intervention: Minimalistic running shoes
Number of subjects: 36
Study 22823855 — intervention group
Group type: EXPERIMENTAL
Intervention: 21st birthday in-person BASICS
Number of subjects: 599
Study 22823855 — intervention group
Group type: EXPERIMENTAL
Intervention: 21st birthday web BASICS
Number of subjects: 599
Study 22823855 — intervention group
Group type: EXPERIMENTAL
Intervention: 21st birthday in-person BASICS plus friend intervention
Number of subjects: 599
Study 22823855 — intervention group
Group type: EXPERIMENTAL
Intervention: 21st birthday web BASICS plus friend intervention
Number of subjects: 599
Study 22823855 — intervention group
Group type: EXPERIMENTAL
Intervention: BASICS
Number of subjects: 599
Study 22823855 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 599
Study 20004617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 217
Study 20004617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 217
Study 20004617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 0.3 mg/kg
Number of subjects: 217
Study 18273431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 0
Study 18273431 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12775400 — intervention group
Group type: EXPERIMENTAL
Intervention: Camberwell Assessment of Need for the Elderly (CANE) feedback
Number of subjects: 112
Study 12775400 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 112
Study 10667641 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF), 1,000 mg/day
Number of subjects: 10000
Study 9330022 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 or 30 mg/day
Number of subjects: 475
Study 9330022 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 or 60 mg/day
Number of subjects: 475
Study 9330022 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 60 or 90 mg/day
Number of subjects: 475
Study 9330022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 8418781 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of antibiotic therapy for low-risk group (n=144)
Number of subjects: 170
Study 8418781 — intervention group
Group type: COMPARATOR
Intervention: 5 days of antibiotic therapy for mid to high-risk group
Number of subjects: 170
Study 8418781 — intervention group
Group type: COMPARATOR
Intervention: 5 days of antibiotic therapy (historic control subjects)
Number of subjects: 170
Study 3091975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 600 mg per os
Number of subjects: 18
Study 3091975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28612911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, clopidogrel, and tirofiban (Group B)
Number of subjects: 258
Study 28612911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, ticagrelor, and tirofiban (Group C)
Number of subjects: 258
Study 28612911 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (Control Group A)
Number of subjects: 258
Study 25411159 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus‐A9‐eluting biodegradable-polymer drug‐eluting stents (BP‐DES)
Number of subjects: 2291
Study 25411159 — intervention group
Group type: EXPERIMENTAL
Intervention: Second‐generation everolimus‐eluting durable‐polymer drug‐eluting stents (DP‐DES)
Number of subjects: 2291
Study 25411159 — intervention group
Group type: COMPARATOR
Intervention: Thin‐strut silicon‐carbide‐coated bare-metal stents (BMS)
Number of subjects: 2291
Study 25411159 — intervention group
Group type: EXPERIMENTAL
Intervention: All stent groups
Number of subjects: 2291
Study 23647756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular fields (n=79)
Number of subjects: 164
Study 23647756 — intervention group
Group type: COMPARATOR
Intervention: Conformal fields (n=85)
Number of subjects: 164
Study 21092936 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual positive memory imagery
Number of subjects: 17
Study 21092936 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual soothing imagery
Number of subjects: 17
Study 21092936 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracting task
Number of subjects: 17
Study 21092936 — intervention group
Group type: COMPARATOR
Intervention: Neutral comparison condition
Number of subjects: 17
Study 19230897 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-channel aEEG monitoring (visible group)
Number of subjects: 0
Study 19230897 — intervention group
Group type: COMPARATOR
Intervention: Limited-channel aEEG monitoring (blinded group)
Number of subjects: 0
Study 17279845 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for closure (NFC)
Number of subjects: 0
Study 17279845 — intervention group
Group type: COMPARATOR
Intervention: Consensus motives
Number of subjects: 0
Study 15182277 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day theophylline for 4 weeks
Number of subjects: 11
Study 15182277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11160544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) until 6 months
Number of subjects: 260
Study 11160544 — intervention group
Group type: COMPARATOR
Intervention: Solid foods (SF) introduced between 4 and 6 months
Number of subjects: 260
Study 9783616 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapandji pinning
Number of subjects: 98
Study 9783616 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and plaster application
Number of subjects: 98
Study 7614398 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate and short‐term postoperative instillation of peplomycin sulfate
Number of subjects: 46
Study 7614398 — intervention group
Group type: COMPARATOR
Intervention: Simple irrigation (control)
Number of subjects: 46
Study 3580317 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration with saline before the episiotomy repair
Number of subjects: 0
Study 3580317 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (control group)
Number of subjects: 0
Study 31025828 — intervention group
Group type: EXPERIMENTAL
Intervention: Life story work (LSW) intervention, participants worked with a volunteer to prepare a life storybook.
Number of subjects: 244
Study 31025828 — intervention group
Group type: COMPARATOR
Intervention: Control group participated in a social program.
Number of subjects: 244
Study 26642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Grassland-survival scenario (Studies 1-3)
Number of subjects: 0
Study 26642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating words for pleasantness (Study 2)
Number of subjects: 0
Study 26642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit learning (Study 3)
Number of subjects: 0
Study 26642740 — intervention group
Group type: COMPARATOR
Intervention: Non-survival scenario of moving to a foreign land (Study 1)
Number of subjects: 0
Study 26642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-survival scenario of moving to a foreign land (Study 2)
Number of subjects: 0
Study 26642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning a trip as a tour guide (Study 3)
Number of subjects: 0
Study 26642740 — intervention group
Group type: COMPARATOR
Intervention: Control study (Study 4)
Number of subjects: 0
Study 25876611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg daily for one month and then 10 mg daily for two months
Number of subjects: 20
Study 25876611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24064347 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 38
Study 24064347 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 21532740 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz method
Number of subjects: 343
Study 21532740 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOTAC method
Number of subjects: 343
Study 19478341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact and resistance-training exercise (EX)
Number of subjects: 10
Study 19478341 — intervention group
Group type: COMPARATOR
Intervention: Restricted physical activity (NE)
Number of subjects: 10
Study 17299194 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine upstream Gp IIb/IIIa inhibitor administration (n=4605)
Number of subjects: 9207
Study 17299194 — intervention group
Group type: COMPARATOR
Intervention: Deferred selective Gp IIb/IIIa inhibitor administration (n=4602)
Number of subjects: 9207
Study 15685831 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan combined with 5-FU/leucovorin
Number of subjects: 0
Study 15685831 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/leucovorin alone
Number of subjects: 0
Study 11675948 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.7 g/day
Number of subjects: 17
Study 11675948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9637582 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment methods and participant motivations
Number of subjects: 0
Study 9637582 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment and screening processes
Number of subjects: 0